See if you qualify for Noom's weight loss medication option today
Endogenous GLP-1 is rapidly degraded primarily by dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and renal clearance, resulting in a half-life of approximately 2 minutes
ELU-GLP3 engages three complementary receptor pathways simultaneously
Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) showed average weight reductions of up to approximately 24% over 48 weeks at the highest doses studied, primarily in adults without type 2 diabetes
Here are some of the most popular treatments being advertised and a summary of what we know about them
Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of our products, including those produced from the NPM-115 and NPM-119 clinical programs